RAS blockers may protect patients with T2DM from pneumonia
Findings from the Australian cohort could be useful in the COVID-19 pandemic, researchers suggest
People with type 2 diabetes mellitus (T2DM) who are taking renin-angiotensin system (RAS) blockers may be reducing their risk of hospitalisation for a severe lower respiratory tract infection, Australian researchers say.